281 related articles for article (PubMed ID: 28581676)
21. Profiling of Epstein-Barr virus-encoded microRNAs in nasopharyngeal carcinoma reveals potential biomarkers and oncomirs.
Wong AM; Kong KL; Tsang JW; Kwong DL; Guan XY
Cancer; 2012 Feb; 118(3):698-710. PubMed ID: 21720996
[TBL] [Abstract][Full Text] [Related]
22. Increased Expression of Phosphatidylinositol 3-Kinase p110α and Gene Amplification of PIK3CA in Nasopharyngeal Carcinoma.
Yip WK; He PY; Abdullah MA; Yusoff S; Seow HF
Pathol Oncol Res; 2016 Apr; 22(2):413-9. PubMed ID: 26581613
[TBL] [Abstract][Full Text] [Related]
23. Investigational drugs for nasopharyngeal carcinoma.
Ma BBY; Hui EP; Chan ATC
Expert Opin Investig Drugs; 2017 Jun; 26(6):677-685. PubMed ID: 28446055
[TBL] [Abstract][Full Text] [Related]
24. Survival analysis of patients with advanced-stage nasopharyngeal carcinoma according to the Epstein-Barr virus status.
Peng H; Chen L; Zhang Y; Guo R; Li WF; Mao YP; Tan LL; Sun Y; Zhang F; Liu LZ; Tian L; Lin AH; Ma J
Oncotarget; 2016 Apr; 7(17):24208-16. PubMed ID: 27008701
[TBL] [Abstract][Full Text] [Related]
25. Expression of Epstein-Barr virus-encoded latent membrane protein (LMP-1), p16 and p53 proteins in nonendemic nasopharyngeal carcinoma (NPC): a clinicopathological study.
Rosales-Pérez S; Cano-Valdez AM; Flores-Balcázar CH; Guedea-Edo F; Lino-Silva LS; Lozano-Borbalas A; Navarro-Martín A; Poitevin-Chacón A
Arch Med Res; 2014 Apr; 45(3):229-36. PubMed ID: 24606815
[TBL] [Abstract][Full Text] [Related]
26. Prevalent somatic BRCA1 mutations shape clinically relevant genomic patterns of nasopharyngeal carcinoma in Southeast Europe.
Fountzilas G; Psyrri A; Giannoulatou E; Tikas I; Manousou K; Rontogianni D; Ciuleanu E; Ciuleanu T; Resiga L; Zaramboukas T; Papadopoulou K; Bobos M; Chrisafi S; Tsolaki E; Markou K; Giotakis E; Koutras A; Psoma E; Kalogera-Fountzila A; Skondra M; Bamia C; Pectasides D; Kotoula V
Int J Cancer; 2018 Jan; 142(1):66-80. PubMed ID: 28857155
[TBL] [Abstract][Full Text] [Related]
27. Identification of genomic mutations associated with clinical outcomes of induction chemotherapy in patients with head and neck squamous cell carcinoma.
Ock CY; Son B; Keam B; Lee SY; Moon J; Kwak H; Kim S; Kim TM; Jeon YK; Kwon SK; Hah JH; Lee SH; Kwon TK; Kim DW; Wu HG; Sung MW; Heo DS
J Cancer Res Clin Oncol; 2016 Apr; 142(4):873-83. PubMed ID: 26677030
[TBL] [Abstract][Full Text] [Related]
28. RPA3 is a potential marker of prognosis and radioresistance for nasopharyngeal carcinoma.
Qu C; Zhao Y; Feng G; Chen C; Tao Y; Zhou S; Liu S; Chang H; Zeng M; Xia Y
J Cell Mol Med; 2017 Nov; 21(11):2872-2883. PubMed ID: 28557284
[TBL] [Abstract][Full Text] [Related]
29. Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix.
Wright AA; Howitt BE; Myers AP; Dahlberg SE; Palescandolo E; Van Hummelen P; MacConaill LE; Shoni M; Wagle N; Jones RT; Quick CM; Laury A; Katz IT; Hahn WC; Matulonis UA; Hirsch MS
Cancer; 2013 Nov; 119(21):3776-83. PubMed ID: 24037752
[TBL] [Abstract][Full Text] [Related]
30. Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations.
Ross JS; Wang K; Khaira D; Ali SM; Fisher HA; Mian B; Nazeer T; Elvin JA; Palma N; Yelensky R; Lipson D; Miller VA; Stephens PJ; Subbiah V; Pal SK
Cancer; 2016 Mar; 122(5):702-11. PubMed ID: 26651075
[TBL] [Abstract][Full Text] [Related]
31. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L
J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
[TBL] [Abstract][Full Text] [Related]
32. Constitutive activation of distinct NF-κB signals in EBV-associated nasopharyngeal carcinoma.
Chung GT; Lou WP; Chow C; To KF; Choy KW; Leung AW; Tong CY; Yuen JW; Ko CW; Yip TT; Busson P; Lo KW
J Pathol; 2013 Nov; 231(3):311-22. PubMed ID: 23868181
[TBL] [Abstract][Full Text] [Related]
33. EBV Infection and Glucose Metabolism in Nasopharyngeal Carcinoma.
Zhang J; Jia L; Tsang CM; Tsao SW
Adv Exp Med Biol; 2017; 1018():75-90. PubMed ID: 29052133
[TBL] [Abstract][Full Text] [Related]
34. Characterization of Clinical Cases of Collecting Duct Carcinoma of the Kidney Assessed by Comprehensive Genomic Profiling.
Pal SK; Choueiri TK; Wang K; Khaira D; Karam JA; Van Allen E; Palma NA; Stein MN; Johnson A; Squillace R; Elvin JA; Chmielecki J; Yelensky R; Yakirevich E; Lipson D; Lin DI; Miller VA; Stephens PJ; Ali SM; Ross JS
Eur Urol; 2016 Sep; 70(3):516-21. PubMed ID: 26149668
[TBL] [Abstract][Full Text] [Related]
35. [Screening for mutations in the hotspot mutation regions of PIK3CA gene in nasopharyngeal carcinoma].
Liu P; Li DJ; Qin HD; Zhang RH; Chen LZ; Zeng YX
Ai Zheng; 2007 Jan; 26(1):15-20. PubMed ID: 17222361
[TBL] [Abstract][Full Text] [Related]
36. A retrospective cohort study of nasopharyngeal adenocarcinoma: a rare histological type of nasopharyngeal cancer.
Guo ZM; Liu WW; He JH
Clin Otolaryngol; 2009 Aug; 34(4):322-7. PubMed ID: 19673979
[TBL] [Abstract][Full Text] [Related]
37. Epstein-Barr Virus-Induced VEGF and GM-CSF Drive Nasopharyngeal Carcinoma Metastasis via Recruitment and Activation of Macrophages.
Huang D; Song SJ; Wu ZZ; Wu W; Cui XY; Chen JN; Zeng MS; Su SC
Cancer Res; 2017 Jul; 77(13):3591-3604. PubMed ID: 28484077
[TBL] [Abstract][Full Text] [Related]
38. Retrospective analysis of oncogenic human papilloma virus and Epstein-Barr virus prevalence in Turkish nasopharyngeal cancer patients.
Tatlı Doğan H; Kılıçarslan A; Doğan M; Süngü N; Güler Tezel G; Güler G
Pathol Res Pract; 2016 Nov; 212(11):1021-1026. PubMed ID: 27640103
[TBL] [Abstract][Full Text] [Related]
39. The protective role of polymorphism MKK4-1304 T>G in nasopharyngeal carcinoma is modulated by Epstein-Barr virus' infection status.
Zheng J; Liu B; Zhang L; Jiang L; Huang B; You Y; Jiang Q; Zhang S; Lu J; Zhou Y
Int J Cancer; 2012 May; 130(9):1981-90. PubMed ID: 21702039
[TBL] [Abstract][Full Text] [Related]
40. Activation of lytic cycle of Epstein-Barr virus by suberoylanilide hydroxamic acid leads to apoptosis and tumor growth suppression of nasopharyngeal carcinoma.
Hui KF; Ho DN; Tsang CM; Middeldorp JM; Tsao GS; Chiang AK
Int J Cancer; 2012 Oct; 131(8):1930-40. PubMed ID: 22261816
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
